Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer
E Kudelova, M Smolar, V Holubekova… - International Journal of …, 2022 - mdpi.com
Heterogeneity of triple-negative breast cancer is well known at clinical, histopathological,
and molecular levels. Genomic instability and greater mutation rates, which may result in the …
and molecular levels. Genomic instability and greater mutation rates, which may result in the …
Introducing neoadjuvant immunotherapy for colorectal cancer: advancing the frontier
A Orhan, TF Justesen, H Raskov, C Qvortrup… - Annals of …, 2025 - journals.lww.com
Objective: To give surgeons a review of the current and future use of neoadjuvant
immunotherapy in patients with localized colorectal cancer (CRC). Background …
immunotherapy in patients with localized colorectal cancer (CRC). Background …
IMMUNOREACT 0: Biopsy‐based immune biomarkers as predictors of response to neoadjuvant therapy for rectal cancer—A systematic review and meta‐analysis
A Stepanyan, M Fassan, G Spolverato… - Cancer …, 2023 - Wiley Online Library
Background The main therapy for rectal cancer patients is neoadjuvant therapy (NT)
followed by surgery. Immune biomarkers are emerging as potential predictors of the …
followed by surgery. Immune biomarkers are emerging as potential predictors of the …
CD3D is an independent prognostic factor and correlates with immune infiltration in gastric cancer
L Yuan, J Xu, Y Shi, Z Jin, Z Bao, P Yu, Y Wang… - Frontiers in …, 2022 - frontiersin.org
The protein encoded by CD3D is part of the T-cell receptor/CD3 complex (TCR/CD3
complex) and is involved in T-cell development and signal transduction. Previous studies …
complex) and is involved in T-cell development and signal transduction. Previous studies …
[HTML][HTML] Digitally assessed lymphocyte infiltration in rectal cancer biopsies is associated with pathological response to neoadjuvant therapy
DNM Jepsen, H Høeg, M Bzorek, A Orhan, JO Eriksen… - Human Pathology, 2024 - Elsevier
A frequently used treatment strategy in locally advanced rectal cancer (RC) is neoadjuvant
therapy followed by surgery. Patients treated with neoadjuvant therapy achieve varying …
therapy followed by surgery. Patients treated with neoadjuvant therapy achieve varying …
Clinical and prognostic significance of perioperative change in red cell distribution width in patients with esophageal squamous cell carcinoma
P Zhang, S Wang, J Wu, Q Song - BMC cancer, 2023 - Springer
Background Numerous studies have reported the prognostic significance of the red cell
distribution width (RDW) in patients with esophageal squamous cell carcinoma (ESCC), but …
distribution width (RDW) in patients with esophageal squamous cell carcinoma (ESCC), but …
Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal …
S Sano, T Akiyoshi, N Yamamoto, Y Hiyoshi… - Clinical Colorectal …, 2023 - Elsevier
Background Neoadjuvant chemoradiotherapy (CRT) is the standard treatment for advanced
rectal cancer. Yet, the response to CRT varies from complete response to zero tumor …
rectal cancer. Yet, the response to CRT varies from complete response to zero tumor …
[HTML][HTML] Tumor Immune Microenvironment Biomarkers for Recurrence Prediction in Locally Advanced Rectal Cancer Patients after Neoadjuvant Chemoradiotherapy
JE Hwang, SS Kim, HJ Bang, HJ Kim, HJ Shim… - Cancers, 2024 - mdpi.com
Simple Summary This study aimed to identify prognostic factors by combining
clinicopathologic parameters with tumor microenvironment (TME) biomarkers in patients …
clinicopathologic parameters with tumor microenvironment (TME) biomarkers in patients …
Tumor-infiltrating lymphocytes, PD-L1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from …
A Giatromanolaki, C Kavazis, AG Gkegka, M Kouroupi… - Immunobiology, 2023 - Elsevier
Introduction Mismatch repair deficiency, immunological fertility, and PD-L1 expression status
are key histopathological and molecular features defining tumor responsiveness to …
are key histopathological and molecular features defining tumor responsiveness to …
[HTML][HTML] Low CD8+ Density Variation and R1 Surgical Margin as Independent Predictors of Early Post-Resection Recurrence in HCC Patients Meeting Milan Criteria
R Stulpinas, I Jakiunaite, A Sidabraite, A Rasmusson… - Current …, 2024 - mdpi.com
Our study included 41 patients fulfilling the Milan criteria preoperatively and aimed to identify
individuals at high risk of post-resection HCC relapse, which occurred in 18 out of 41 …
individuals at high risk of post-resection HCC relapse, which occurred in 18 out of 41 …